Advanced stage cancer patients provided with personalized treatments based on their tumor’s molecular information were more likely to survive or experience a longer period without disease progression. Advanced cancer patients being treated at the Moores Cancer Center at UC San Diego Health (CA, USA) were more likely to survive or experience a longer period without disease progression if they received precision cancer treatment. In order to initiate the study, which was published recently in Nature Communications, a molecular tumor advisory board was established comprised of experts in basic, translational and clinical research across multiple disciplines. They used information from patients’...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!